Omer, thank you for your posting.
What a happy day for the ones who are long. Staying in positive territory all day while the financial world around is sinking in ashes is a sedative for our distressed nerves.
Not knowing what would come later on I used the early hours to add some more shares to my portfolio, and now I am even more happy to see (at least for today :-) ), that I have not been wrong. But as nearly everyone here I see PARS as a longterm investment.
But I can understand when investors are getting nervous, and I am not going to blame them. If one was fully invested 3 month ago and does not have the chance to use these prices to average down, the losses are frightening. Even taking into account a possible 50 % increase after publishing positive data on HU211, based on $ 1,75 this would lead to $ 2,625 - still far below the year's high.
On the long run PARS has more than only one good reason for an increasing share price on its side. You mentioned them all. But I want to stress one reason, that was mentioned only aside: The economical crisis might have a big impact on the worldwide economy, and what we have seen right now might only just be the start. But PARS, together with other companies in the pharma/biotech business, could go through this crisis quite comfortable. And this will strengthen the relative position within an investors portfolio.
Even if PARS is hit heavily on the beginning of the crisis (as it was the last few weeks), it will recover more quickly than the rest of the market. And this is going to lead to even more market interest. So in the long run, even a bear market could turn out to be positive for PARS.
The only thing I fear right now is somebody using the chance to snatch up PARS at these discount prices, like Elan did with Neurex. In this case we all would loose.
Hoping to see you win,
Richard |
